NIN/NINDS HEAL Program Grants Prestigious UH3 Award to the University of Miami, Principal Investigator Roy C. Levitt M.D, to Fund Clinical Development of Adolore BioTherapeutics’ Gene Therapy Program for the Treatment of Chronic Osteoarthritis Knee Pain

by | Oct 3, 2023 | Press Releases

UH3 Award follows the successful completion of an initial NIH/NINDS HEAL UG3 grant for which all pre-clinical milestones were metThis NIH/NINDS HEAL UH3 Award will support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study in patients,...

Adolore Biotherapeutics Presents Encouraging Preclinical Data of Innovative Gene Therapy Approach to Chronic Pain at the 2023 American Society of Pain and Neuroscience (ASPN) Annual Conference

by | Jul 17, 2023 | Press Releases

Data demonstrate preclinical proof-of-concept for rdHSV-based CA8* gene therapy as a disease-modifying long-acting local anesthetic that has the potential to replace opioids in chronic osteoarthritis (OA) knee pain managementCompany continues to advance development of...

Adolore Biotherapeutics Enters into Exclusive License Agreement with University of Pittsburgh for Patents Protecting Non-Toxic Replication-Defective HSV Vectors for Efficient Gene Delivery Applications and Complementing Cells for Their Production

by | May 23, 2023 | Press Releases

Company developing next generation, disease-modifying, non-opioid analgesic gene therapies for the treatment of chronic painDELRAY BEACH, FL / May 23, 2023 / Adolore Biotherapeutics, Inc. (“Adolore” or the “Company”) a biotechnology company...